Fibrosis Driving Myofibroblast Precursors in MPN and New Therapeutic Pathways

Overview

Journal Hemasphere

Publisher Wiley

Specialty Hematology

Date 2022 Mar 21

PMID 35309783

Authors

Helene F E Gleitz

Jessica E Pritchard

Rafael Kramann

Rebekka K Schneider

Affiliations

Soon will be listed here.

Citing Articles

Inhibition of proinflammatory signaling impairs fibrosis of bone marrow mesenchymal stromal cells in myeloproliferative neoplasms.

Vukotic M, Kapor S, Dragojevic T, dikic D, Ajtic O, Diklic M Exp Mol Med. 2022; 54(3):273-284.

PMID: 35288649 PMC: 8980093. DOI: 10.1038/s12276-022-00742-y.

References

Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464):1054-61. DOI: 10.1016/S0140-6736(05)71142-9. View

Sasaki K, Gotlib J, Mesa R, Newberry K, Ravandi F, Cortes J . Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. Leuk Lymphoma. 2015; 56(7):2092-7. PMC: 4919663. DOI: 10.3109/10428194.2014.984703. View

Rambaldi A, Barbui T, Barosi G . From palliation to epigenetic therapy in myelofibrosis. Hematology Am Soc Hematol Educ Program. 2008; :83-91. DOI: 10.1182/asheducation-2008.1.83. View

Tefferi A . JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood. 2012; 119(12):2721-30. DOI: 10.1182/blood-2011-11-395228. View

Arranz L, Sanchez-Aguilera A, Martin-Perez D, Isern J, Langa X, Tzankov A . Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature. 2014; 512(7512):78-81. DOI: 10.1038/nature13383. View

Schneider R, Mullally A, Dugourd A, Peisker F, Hoogenboezem R, van Strien P . Gli1 Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target. Cell Stem Cell. 2017; 20(6):785-800.e8. PMC: 6485654. DOI: 10.1016/j.stem.2017.03.008. View

Verstovsek S, Savona M, Mesa R, Dong H, Maltzman J, Sharma S . A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis. Br J Haematol. 2017; 176(6):939-949. DOI: 10.1111/bjh.14501. View

Decker M, Martinez-Morentin L, Wang G, Lee Y, Liu Q, Leslie J . Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis. Nat Cell Biol. 2017; 19(6):677-688. PMC: 5801040. DOI: 10.1038/ncb3530. View

Ding L, Saunders T, Enikolopov G, Morrison S . Endothelial and perivascular cells maintain haematopoietic stem cells. Nature. 2012; 481(7382):457-62. PMC: 3270376. DOI: 10.1038/nature10783. View

10.

Kralovics R, Passamonti F, Buser A, Teo S, Tiedt R, Passweg J . A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352(17):1779-90. DOI: 10.1056/NEJMoa051113. View

11.

Badar T, Kantarjian H, Ravandi F, Jabbour E, Borthakur G, Cortes J . Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res. 2015; 39(9):950-6. PMC: 4546869. DOI: 10.1016/j.leukres.2015.06.001. View

12.

Kramann R, Schneider R . The identification of fibrosis-driving myofibroblast precursors reveals new therapeutic avenues in myelofibrosis. Blood. 2018; 131(19):2111-2119. DOI: 10.1182/blood-2018-02-834820. View